Literature DB >> 34046868

Association Between Endothelial Nitric Oxide Synthase (eNOS) -786 T/C and 27-bp VNTR 4b/a Polymorphisms and Preeclampsia Development.

Tamara Sljivancanin Jakovljevic1, Olivera Kontic-Vucinic2,3, Nadja Nikolic4, Jelena Carkic4, Jelena Stamenkovic2,3, Ivan Soldatovic5, Jelena Milasin4.   

Abstract

The aim of the present study was to analyze the distribution of genotypes and haplotypes of functional eNOS gene polymorphisms in the promoter (-786 T/C), intron 4 (VNTR4b/a) and exon 7 (894 G/T), in Serbian population of pregnant women, and establish a possible association between these polymorphisms and preeclampsia development. DNA was isolated from venous blood samples of 50 heathy pregnant women and 50 preeclampsia patients. Polymerase Chain Reaction/Restriction Fragment Length Polymorphism (PCR/RFLP) technique, with appropriate sets of primers and specific restriction enzymes, was used to determine polymorphisms in eNOS gene. Statistical analysis was done using the SPSS and HAPLOVIEW software packages. eNOS -786 T/C polymorphism was significantly associated with preeclampsia (P = 0.006). Homozygotes for the VNTR polymorphism had also an elevated risk of developing preeclampsia (OR=7.68, 95%CI (0.89-65.98)), especially the mild (OR=9.33, 95%CI (0.98-88.57)) and late form (OR=8.52, 95%CI (0.90-80.58)). The 894 G/T polymorphism was not associated with preeclampsia. "G-C-b" and "T-4a-T" haplotypes were more frequent in preeclampsia, though without reaching statistical significance. -786 T/C and VNTR 4b/a eNOS gene polymorphisms were associated with preeclampsia risk in Serbian patients.
© 2021. Society for Reproductive Investigation.

Entities:  

Keywords:  Endothelial nitric oxide synthase; Gene polymorphisms; Haplotypes; Preeclampsia

Mesh:

Substances:

Year:  2021        PMID: 34046868     DOI: 10.1007/s43032-021-00632-0

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  71 in total

1.  βhCG and PAPP-A in first trimester: predictive factors for preeclampsia?

Authors:  Barbara Mikat; Anna Zeller; André Scherag; Karla Drommelschmidt; Rainer Kimmig; Markus Schmidt
Journal:  Hypertens Pregnancy       Date:  2011-12-09       Impact factor: 2.108

2.  Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.

Authors:  Ranjit Akolekar; Argyro Syngelaki; Rita Sarquis; Mona Zvanca; Kypros H Nicolaides
Journal:  Prenat Diagn       Date:  2011-01       Impact factor: 3.050

Review 3.  Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia.

Authors:  Chun Lam; Kee-Hak Lim; S Ananth Karumanchi
Journal:  Hypertension       Date:  2005-10-17       Impact factor: 10.190

Review 4.  The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia.

Authors:  Langeza Saleh; Koen Verdonk; Willy Visser; Anton H van den Meiracker; A H Jan Danser
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-01-10

5.  First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia.

Authors:  E J Wortelboer; M P H Koster; H S Cuckle; P H Stoutenbeek; P C J I Schielen; G H A Visser
Journal:  BJOG       Date:  2010-10       Impact factor: 6.531

6.  Heme oxygenase expression in human placenta and placental bed: reduced expression of placenta endothelial HO-2 in preeclampsia and fetal growth restriction.

Authors:  A Barber; S C Robson; L Myatt; J N Bulmer; F Lyall
Journal:  FASEB J       Date:  2001-05       Impact factor: 5.191

7.  Angiogenin and vascular endothelial growth factor in pregnancies complicated by preeclampsia.

Authors:  M Shaarawy; F Al-Sokkary; M Sheba; O Wahba; H O Kandil; I Abdel-Mohsen
Journal:  Int J Gynaecol Obstet       Date:  2004-12-09       Impact factor: 3.561

8.  Maternal serum activin a at 11-13 weeks of gestation in hypertensive disorders of pregnancy.

Authors:  Ranjit Akolekar; Adolfo Etchegaray; Yi Zhou; Nerea Maiz; Kypros H Nicolaides
Journal:  Fetal Diagn Ther       Date:  2009-09-22       Impact factor: 2.587

9.  Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study.

Authors:  R Gonen; R Shahar; Y I Grimpel; I Chefetz; M Sammar; H Meiri; Y Gibor
Journal:  BJOG       Date:  2008-11       Impact factor: 6.531

10.  Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia.

Authors:  Sarosh Rana; Camille E Powe; Saira Salahuddin; Stefan Verlohren; Frank H Perschel; Richard J Levine; Kee-Hak Lim; Julia B Wenger; Ravi Thadhani; S Ananth Karumanchi
Journal:  Circulation       Date:  2012-01-18       Impact factor: 29.690

View more
  1 in total

Review 1.  Genetic Background of Fetal Growth Restriction.

Authors:  Beata Anna Nowakowska; Katarzyna Pankiewicz; Urszula Nowacka; Magdalena Niemiec; Szymon Kozłowski; Tadeusz Issat
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.